<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61076">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02310828</url>
  </required_header>
  <id_info>
    <org_study_id>AC-CLUSTPREV-1</org_study_id>
    <nct_id>NCT02310828</nct_id>
  </id_info>
  <brief_title>The Efficacy of L-cysteine in Prevention of Cluster Headache</brief_title>
  <official_title>The Efficacy of L-cysteine in Prevention of Cluster Headache. Randomized Intervention Trial With a Medical Device (Acetium® Capsules)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biohit Oyj</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Finnish Funding Agency for Technology and Innovation (TEKES)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biohit Oyj</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to validate the novel hypothesis that daily use of L-cysteine
      (Acetium® capsules) is an effective means to decrease the frequency of (or completely abort)
      the attacks of cluster headache.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The frequency of headache attacks per week</measure>
    <time_frame>1 month</time_frame>
    <description>The frequency of headache attacks per week, either during the entire treatment period or during the last treatment interval is compared with the baseline frequencies, to disclose differences between the two study arms.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cluster Headache</condition>
  <arm_group>
    <arm_group_label>Acetium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will administer Acetium capsules (100mg l-cysteine) twice a day for one month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient will administer placebo capsules twice a day for one month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetium</intervention_name>
    <description>Capsule for oral administration contains L-cysteine 100mg</description>
    <arm_group_label>Acetium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo capsule matching Acetium for oral administration.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years male/female

          -  episodic and chronic cluster headache

          -  the subjects should report cluster headache attacks with the frequency from one every
             second day up to five per day. The individual attacks should last from 15 minutes to
             3h.

        Exclusion Criteria:

          -  patients who meet the International Classification of Headache Disorders II criteria
             for medication overuse

          -  patients who have taken anti-psychotics or anti-depressant medications during the
             previous 3 months

          -  patients who abuse alcohol or other drugs

          -  potentially fertile and sexually active women who do not practise contraception

          -  other acute or chronic pain disorders

          -  severe psychiatric disease

          -  infections

          -  malignancy

          -  short life expectancy

          -  cardiovascular disease

          -  cerebrovascular disease

          -  uncontrolled hypertension

          -  degenerative central nervous system diseases

          -  pregnant and lactating women

          -  regular users of Acetium capsules for other indications

          -  renal dysfunction or cystinuria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kari Syrjänen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Biohit Oyj</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lääkärikeskus Aava, Helsingin Päänsärkykeskus Oy</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikko Kallela, MD, PhD</last_name>
      <phone>0035850 5910702</phone>
      <email>mikko.kallela@pp.fimnet.fi</email>
    </contact>
    <contact_backup>
      <last_name>Anne Nyrhinen</last_name>
      <phone>0035850 5910702</phone>
      <email>anne.nyrhinen@aava.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Mikko Kallela, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markus Färkkilä, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Terveystalo, Kamppi</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Keski-Säntti, MD, PhD</last_name>
      <phone>00358503738938</phone>
      <email>petra.keski-santti@terveystalo.com</email>
    </contact>
    <investigator>
      <last_name>Petra Keski-Säntti, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Terveystalo, Jyväskylä</name>
      <address>
        <city>Jyväskylä</city>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matti Ilmavirta, MD, PhD</last_name>
      <phone>0035850-5631802</phone>
      <email>Matti.ilmavirta@terveystalo.com</email>
    </contact>
    <contact_backup>
      <last_name>Anna Kinnunen</last_name>
      <phone>0035850-5631802</phone>
      <email>Anna.Kinnunen@terveystalo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Matti Ilmavirta, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Terveystalo, Oulu</name>
      <address>
        <city>Oulu</city>
        <zip>90101</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikko Kärppä, MD, PhD</last_name>
      <phone>0035810 345 2931</phone>
      <email>mikko.karppa@oulu.fi</email>
    </contact>
    <contact_backup>
      <last_name>Jaana Vainionpää</last_name>
      <phone>0035810 345 2931</phone>
      <email>jaana.vainionpaa@terveystalo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mikko Kärppä, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Terveystalo, Tampere</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marja-Liisa Sumelahti, MD, PhD</last_name>
      <phone>040 587 4149</phone>
      <email>marja-liisa.sumelahti@uta.fi</email>
    </contact>
    <contact_backup>
      <last_name>Outi Salminen</last_name>
      <email>outi.salminen@terveystalo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marja-Liisa Sumelahti, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Terveystalo, Turku</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markku Nissilä, MD</last_name>
      <phone>00358400 788 020</phone>
      <email>markku.nissila@terveystalo.com</email>
    </contact>
    <contact_backup>
      <last_name>Sanna Hannukainen</last_name>
      <phone>00358505220271</phone>
      <email>sanna.hannukainen@terveystalo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Markku Nissilä, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nina Suvanto-Collán, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 20, 2016</lastchanged_date>
  <firstreceived_date>December 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cluster headache</keyword>
  <keyword>Migrainous neuralgia</keyword>
  <keyword>Horton's headache</keyword>
  <keyword>Histaminic cephalalgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Cluster Headache</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
